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Medical thoracoscopy (MT) is increasingly used in the UK
now for the investigation of unexplained pleural effusion,
especially malignant pleural effusion which can result in
cytology negative pleural aspirates in 40e60% of cases
depending on the underlying pathology.1 MT allows
drainage of the effusion, multiple biopsies under direct
vision (giving a far higher diagnostic yield than pleural
aspiration, 95% versus 40e60% respectively) and an effec-
tive pleurodesis in one visit.1,2 Therefore, MT can shorten
the length of stay of patients with unexplained pleural
effusion by avoiding the need for extra tests (specifically
Abrams or image-guided pleural biopsy after a non-
diagnostic aspirate or even a video-assisted thoracoscopic
surgical (VATS) biopsy), avoiding the need for separate
insertion of a chest drain (after tests have confirmed the
need to do this) and avoiding the need to wait for adequate
drainage before administering a sclerosant to achieve
a pleurodesis which is not usually as effective as via MT
especially if from a lung or breast cancer.3 By also removing
the need for extra tests (with potential morbidity) and
achieving a diagnosis in one visit as well as shortening
length of stay, MT improves the quality and safety of the
patient admission with an unexplained pleural effusion.
A theoretical cost analysis was conducted based on the
observations from a previous MT performance study at the
same institution4 using the costings from the 2010/11
National Tariffs.5 A best case scenario of 7 days has been
extrapolated from studies in the literature6,7 for the non-
MT investigation admission length with a worst case
scenario of 10 days (length of stay for the MT pathway was
4.5 days derived from the previous study4). Costs to the
Primary Care Trust have been calculated using the 2010/11
tariffs for each pleural investigation. Anticipated yields
from each investigation were derived from those in the
British Thoracic Society guidelines and the previous MT
study.1,4 Local costs of admission stay were calculated on
the basis of £227 per night stay (University Hospitals of
Leicester Trust Corporate Management Accountant
Department, personal communication).
Calculating the difference between cost to the Primary
Care Trust of the investigations and the cost to the NHS Trust0954-6111/$ - see front matter ª 2010 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2010.03.005of the admission stay for a cohort of 125 patients, the MT
pathway would result in a cost saving to the NHS Trust of
£119,448 (or £956 per case) due to both increased tariff-
based revenue but also shorter length of stay. By contrast for
the same 125 cases, the conventional (non-MT) pathway
would result in a cost deficit of between £79,686 (£637 per
case) to £145,308 (£1162 per case) for best and worst case
scenarios respectively.
We have not calculated the exact cost to the NHS Trust of
the procedures themselves so we appreciate this is an
extrapolation. Nevertheless, these data provide a rationale
for developing MT to reduce patient length of stay, perform
a single more effective diagnostic test and therapeutic
procedure in one visit.
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